Keywords
bone turnover markers
menopausal period
ovarectomy hormone replacement therapy
Abstract
In adult life, proper bone metabolism requires efficient regulation of bone formation and resorption processes. Bone turnover markers allow for assessing the rate of bone formation and resorption processes. In menopausal period, female patients experience gradual reduction in blood estradiol levels. The deficit of estrogens leads to enhanced osteoclastogenesis and bone resorption. Alkaline phosphatase (ALP) is a membranebound enzyme that stimulates the osteoblast activity and bone mineralization. It is synthesized by osteoblasts and incorporated into the newly formed bone tissue. The produced enzyme stimulates the osteoblast activity and bone mineralization. The goal of this study is to determine the effect of hormone replacement therapy in postmenopausal women on the expression of alkaline phosphatase gene (ALPL) within the mucosal epithelium of the cheek and in peripheral blood lymphocytes. The studies show that hormone replacement therapy has no significant effect on the increase in ALPL expression within the mucosal epithelium of the cheek. Only in women having undergone ovarectomy (OV), the epithelial ALPL expression level was higher than in the remaining groups.
References
1. Chomczynski P., Sacchi N.: Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-9, 1987.
2. Edman C.D.: Przekwitanie (klimakterium) (1989). In: Menopauza. Red. Buchsbauni HJ. PZWL. Warsaw, p. 34-44.
3. Gajewska J., Ambroszkiewicz J., Laskowska-Klita T.: Wybrane markery obrotu kostnego w surowicy krwi dzieci w zależności od wieku i płci; Wiad, Lek., 2005, 58, 9-10, 2005.
4. Garnero P., Hauser E., Chapuy M.C. et al.: Markers of bone predict hip fractures in elderly women. J Bone Min Res 11, 1531–38, 1996.
5. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D.: Biochemicalmarkers of bone turnover, endogenous hormones and the risk offractures in postmenopausal women. J. Bone Miner. Res., 15, 1526-36, 2000.
6. Garnero P.: Bone markers in osteoporosis. Curr. Osteoporos. Rep., 7, 84–90, 2009.
7. Hansen M., Overgaard K., Riis B., Christiansen C.: Role of peak bonemass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ, 303, 961–64, 1991.
8. Jurkowski P., Mierzwińska-Nastalska E., Kostrzewa-Janicka J.: Use of Biochemical Markers of Bone Turnover in General Medicine and Dentistry. Dent. Med. Probl., 47, 2, 199-205, 2010
9. Karczmarewicz E.: Markery obrotu kostnego. Nieinwazyjna ocena parametrów jakości kości. Osteoforum 2008
10. Karczmarewicz E.: Wartość diagnostyczna markerów obrotu kostnego. Osteoforum 2006.
11. Kraenzlin M.E.: Biochemical Markers of Bone Turnover and Osteoporosis Management. BoneKEy, 4, 191–203, 2007.
12. Lerner U.H.: Bone remodeling in post-menopausal osteoporosis. J. Dent. Res., 85, 584-595, 2006.
13. Marcinowska-Suchowierska (1999): Osteoporoza - diagnostyka, profilaktyka i leczenie. PZWL. Warszawa.
14. Nawawi H.M. et al.: Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis. Malays J Pathol., 23, 79-88, 2001.
15. Naylor K.E., Eastell R.: Measurement of biochemical markers of bone formation. In:Seibel M, Robins S, Bilezikian J, eds. Dynamics of bone and cartilage metabolism. Academic Press, 529–40, 2006.
16. Rachoń D., Myśliwska J., Suchocka-Rachoń K.: Wpływ przezskórnej estrogenoterapii na produkcję interleukiny-6 u kobiet w wieku pomenopauzalnym. Przegl. Menopauz., 2, 22-27, 2002.
17. Rahnama M. et al.: Wpływ stosowania hormonoterapii zastępczej na stężenie fosfatazy zasadowej i fosfatazy kwaśnej w surowicy i ślinie u kobiet z niedoborem estrogenów. Przegl. Menopauz., 6, 506–9, 2012.
18. Schiele F. et al.: Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem., 29, 634-41, 1983.
19. Takahashi M. et al.: Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis. Clin. Endocrinol. (Oxf), 47, 177-83, 1997.
20. Warenik-Szymankiewicz A., Stopień R.: Zastosowanie niskich dawek estrogenów jako nowej strategii w osteoporozie pomenopauzalnej. Terapia, 9, 11, 19-22, 2001.
21. Warenik-Szymankiewicz A.: Hormonalna terapia zastępcza w okresie okołomenopauzalnym. Terapia, 5, 3-14, 1997.
22. Weitzmann M., Pacifici R.: Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest., 116, 1186–94, 2006.
23. Zgliczyński S.: Globalizacja w osteoporozie. JAMA PL, 5(1-2), 75-6, 2003.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2014 Authors